#Coronavirus Innovation in #Biotech, #Hemp/ #Cannabis,
#Tech Stocks (OTCQB: $SING), (OTCQX: $CRLBF), (NASDAQ: $GILD), (OTC: $CYDY), (NASDAQ: $ZM)
Entrepreneurism Thrives as
SinglePoint Inc. Launches USA Made Hemp
Seed Oil Infused Hand Sanitizer
Point Roberts WA, Delta, BC – March 17, 2020 - Investorideas.com, a leading investor news resource covering hemp/
cannabis stocks and coronavirus (COVID-19) stocks issues a snapshot looking at
the eruption of innovation in multiple sectors in the face of today’s ongoing pandemic.
Crisis has always incited innovation, creating winners and losers and this
pandemic is creating a global shift never before witnessed. Companies that are
agile enough to adapt and recognize the change can also seize opportunities by
providing a definite solution; which is what
SinglePoint Inc. (OTCQB: SING) is aiming to do by launching Klen Hands – Hand
Sanitizer with Moisturizing Hemp Seed Oil, made in the USA.
Read this news featuring
SING in full at https://www.investorideas.com/news/2020/biotech/03171CoronavirusInnovation.asp
On March 13th, Friday the 13th,
thought to be an unlucky day by some, SinglePoint Inc. (OTCQB: SING) boldly announced the launch
of Klen Hands, yet another example of
how they have consistently been on top of consumer and industry trends. Already
entrenched in the cannabis and cleantech sectors, during this current crisis, SinglePoint immediately saw the need for a crossover into the health
sector as shelves are being emptied of hand sanitizers.
According
to the press release: “Hand sanitizer is one of the most out of stock products there is in
most all retail locations. We do expect to sell out very quickly. As we move
into uncertain times, we have developed a product to directly combat the
coronavirus. Our hand sanitizer has 62% ethyl alcohol to keep hands klen
(clean) as well as hemp seed oil to keep hands soft and hydrated. Sanitize.
Hydrate. Repeat.”
Klen is currently being produced in SinglePoint's
Carlsbad facility and will ship directly to your location. Orders will be
fulfilled in the order they are received.
"We are working to develop solutions for both
product and technology in order to assist in the effort of combating COVID-19.
As many people know our company has deep ties to the Washington State area. We
believe we can provide solutions in the near term to help with the
dissemination of current, reliable information and in the interim use our
facilities to develop products such as hand sanitizer. We will be releasing
additional resources for individuals in the coming weeks." - Greg
Lambrecht CEO.
Another key trend arising in the cannabis space due
to the coronavirus outbreak, is the boom of cannabis delivery services. Cresco
Labs (CSE:CL)(OTCQX:CRLBF), one of the largest vertically integrated
multistate cannabis operators in the United States recently announced the launch of
a home delivery service for medical cannabis patients in the New Hartford area
of New York.
“Registered medical cannabis patients can place a
home delivery order seven days a week at Sunnyside. Shop with a minimum order
of $80 required for delivery service. Free delivery is available for orders of
$150 or more. Distributed from Cresco’s Sunnyside dispensary in New Hartford,
delivery services are available for patients in the following communities: New
Hartford, Utica, Marcy, Whitesboro, Oriskany, Clinton, Sauquoit, Frankfurt and
Rome.”
Sugarmade, Inc. (OTCQB:SGMD), along with the BudCars Cannabis Delivery Service, announced last week a sharp rise in demand for its cannabis delivery
service, driving an associated 10% week-over-week rise in total sales, over the
past two weeks. The Company believes this dynamic is being driven by the stay-at-home
trend that has emerged in many communities around the world in response to the
global pandemic outbreak of the COVID-19 disease.
It looks like there will also be a huge uptick in
cannabis sales as consumers are buying and hoarding cannabis just like toilet
paper and hand sanitizers.
“Retail stores across the United States have seen
an influx of traffic as Americans seek to stock up on basic supplies. Cannabis
retailers have seen a similar trend, with many consumers choosing to make fewer
trips to dispensaries, instead opting for larger, less frequent purchases as
COVID-19 fears grip the country,” reported a Motley Fool correspondent.
In the pharma and biotech sector we have seen
players from big to small announce potential solutions as they race to find a
vaccine for COVID-19. Gilead Sciences, Inc. (NASDAQ: GILD), a presumed leader, even by the WHO, announced late February the initiation of two Phase 3
clinical studies to evaluate the safety and efficacy of remdesivir in adults
diagnosed with COVID-19 (novel coronavirus). These randomized, open-label,
multicenter studies will enroll approximately 1,000 patients at medical centers
primarily across Asian countries, as well as other countries globally with high
numbers of diagnosed cases, beginning in March. The studies will assess two
dosing durations of remdesivir, administered intravenously. The initiation of
these studies follows the US Food and Drug Administration’s (FDA) rapid review
and acceptance of Gilead’s investigational new drug (IND) filing for remdesivir
for the treatment of COVID-19.
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) announced Friday that it plans to evaluate its amniotic
fluid concentrate, AmnioBoost, in patients with acute respiratory distress
syndrome (ARDS) caused by coronavirus (COVID-19).
AmnioBoost has potential for use in the treatment
of ARDS, which is the principal cause of death in COVID-19 infection. Mortality
in COVID-19 infected patients with the inflammatory lung condition (ARDS) is
reported to approach 50%, and is associated with older age, co-morbidities such
as diabetes, higher disease severity, and elevated markers of inflammation.
Current therapeutic interventions do not appear to improve in-hospital
survival.
CytoDyn Inc. (OTC: CYDY), a
late-stage biotechnology company developing leronlimab (PRO 140), a CCR5
antagonist with the potential for multiple therapeutic indications, announced that the Company has submitted an investigational
new drug (IND) application to the US Food and Drug Administration (FDA) to
conduct a Phase 2 clinical trial with leronlimab (PRO 140) as a therapy for
patients who experience respiratory complications as a result of contracting
the coronavirus disease 2019 (COVID-19).
Looking at the tech sector, there are multitudes of
technology already in place that can be deployed and smart companies are
already on it. According to a report
from CNBC,
“Chinese technology giants are accelerating their efforts in the field of
health-care technology in areas from cloud computing to artificial intelligence
(AI) amid the new coronavirus outbreak. Alibaba (NYSE: BABA), Baidu (NASDAQ: BIDU), Tencent (OTC: TCEHY), Huawei and DiDi have all launched new health
tech features aimed at diagnosing cases and finding a vaccine for the
coronavirus.”
Drone technology is also being used for delivery
and mapping, and companies like Zoom Video Communications, Inc. (NASDAQ: ZM) are expected to see a boost from all the remote
workers.
As we self isolate, social distance and stock up,
let’s be smart as investors and not panic and really look at the bigger picture
unfolding; innovation and entrepreneurism at its best.
Visit
Investorideas.com cannabis and hemp stock directory
Visit
Investorideas.com biotech and coronavirus stocks directory https://www.investorideas.com/BIS/stock_list.asp
Visit
Investorideas.com tech stocks directory
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source
publishing third party news, research and original financial content. Learn
about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and
IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s
original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: this article featuring SING is a paid
for services on Investorideas.co ( two thousand ) Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/
and tickertagstocknews.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Global
investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Get free investor news alerts
Contact
Investorideas.com
800 665 0411
